Targeting Inflammation in Atherosclerosis

Published: 08 April 2022

  • Views:

    Views Icon 20879
  • Likes:

    Heart Icon 7

Overview

Full programme

Part 9 of 9

Inflammatory signalling in atherosclerosis and CKD

Juan Carlos Kaski, Paul M Ridker

Download Transcript

Overview

As we continue to move beyond lipid lowering treatment options and explore novel possibilities targeting residual inflammatory risk, there is a substantial unmet educational need to support cardiologists. Inflammation plays a significant role during atherosclerosis and several lines of evidence suggest that inhibiting the inflammatory cytokines along the IL-6 axis reduces adverse events in CAD.

 

This independent medical educational programme aims to increase knowledge on the causal relationship between inflammation and cardiovascular disease (CVD) – an underappreciated therapeutic target for the prevention of CV progression and events. 

 

Click here to listen to the podcast versions. 

Supported by an unrestricted educational grant from NOVO NORDISK A/S

The information and data provided in this program was updated and correct at the time of the program development, but may be subject to change

Learning Objectives

  • Discuss the complex relationship between inflammation and the development of ASCVD and renal impairment
  • Summarise therapeutic targets of inflammation along the IL-6 axis
  • Recall how hsCRP can be used as a biomarker for inflammation
  • Recall the latest clinical trial and pre-clinical data assessing anti-inflammatory strategies to overcome atherosclerosis and how this relates to current guidance
  • Rationalise the mode of action behind the use of monoclonal antibody therapy along the IL-6–CRP axis
  • Contrast the use of novel treatments targeting inflammation in atherosclerosis with existing therapies that have shown clinical benefit

Target Audience

  • General Cardiologists

More from this programme

Part 1

RESCUE trial

Join Dr Peter Libby (Brigham and Women’s Hospital, Boston, US) as he talks us through the RESCUE trial design and results in this short presentation.

Part 2

CANTOS trial

Prof Paul Ridker (Brigham and Women’s Hospital, Boston, US) provides us with an overview of the CANTOS main trial results and updated results from the ACC 2022.

Part 3

LoDoCo2 trial

In this LoDoCo2 presentation, Dr Aernoud Fiolet (University Medical Center Utrecht, Netherlands) covers the trial design and main results.

Part 4

COLCOT trial

Prof Jean-Claude Tardif (Montreal Heart Institute, Canada) gives us a comprehensive overview of the COLCOT trial.

Part 5

Current guidelines and clinical data

Join Prof Juan Carlos Kaski (St George’s University of London, UK) and Dr Aernoud Fiolet (University Medical Center Utrecht, Netherlands) as they explore topics such as how guidelines currently view anti-inflammatory approaches and main molecules under investigation.

Part 6

Therapeutic targets and mode of action

Prof Juan Carlos Kaski (St George’s University of London, UK) alongside Dr Peter Libby (Brigham and Women’s Hospital, Boston, US) provide us with a short and concise discussion regarding Therapeutic Targets and Mode of Action.

Part 7

Unmet clinical needs in atherosclerosis and chronic kidney disease

Prof Juan Carlos Kaski (St George’s University of London, UK) is joined by Prof Paul Ridker (Brigham and Women’s Hospital, Boston, US) to discuss Unmet Clinical Needs in Atherosclerosis and Chronic Kidney Disease where they cover topics such as elevated hsCRP and chronic kidney disease.

Part 8

Inflammation and atherosclerosis

Inflammation and Atherosclerosis – What is the Link with CKD? Join Prof Juan Carlos Kaski (St George’s University of London, UK) and Prof Lina Badimon (Hospital of Santa Creu and San Pau, Barcelona, Spain) as they discuss that very question.

Part 9

Inflammatory signalling in atherosclerosis and CKD

Inflammatory Signalling in Atherosclerosis and CKD is the topic of interest in this short peer to peer discussion involving Prof Juan Carlos Kaski (St George’s University of London, UK) and Prof Paul Ridker (Brigham and Women’s Hospital, Boston, US).

Faculty Biographies

Juan Carlos Kaski

Juan Carlos Kaski

Professor of Cardiovascular Science

Juan Carlos Kaski is Professor of Cardiovascular Science (Emeritus) at the Molecular and Clinical Sciences Research Institute, St Gorge’s, University of London, and Hon. Consultant Cardiologist at St George’s Hospital and the Royal Brompton Hospital in London, UK.  He is Doctor Honoris Causa of several universities worldwide, a past-President of the International Society of Cardiovascular Pharmacotherapy and Fellow of over 30 scientific societies worldwide. JC Kaski has received numerous national and international awards for his research work and both his clinical and educational activities. Professor Kaski is Chairman-elect, European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy, Editor-in-Chief of the European Cardiology Review Journal, Deputy Editor of the European Heart Journal, Co-Editor of the ESC Handbook on Cardiovascular Pharmacotherapy and editorial board member of JACC and over 20 other scientific journals. Prof Kaski’s research areas include…

View full profile
Paul M Ridker

Paul M Ridker

Senior Physician, Brigham and Women's Hospital Eugene Braunwald Professor of Medicine, Harvard Medical School

Dr Paul M Ridker is director of the Center for Cardiovascular Disease Prevention, a translational research unit at Brigham and Women’s Hospital (BWH). A cardiovascular medicine specialist, he is also the Eugene Braunwald Professor of Medicine at Harvard School of Medicine (HMS).

Dr Ridker received his medical degree from HMS. He then completed an internal medicine residency and a cardiology fellowship at BWH. He has authored over 500 peer-reviewed publications, 150 reviews and book chapters, and five textbooks related to cardiovascular medicine. Dr Ridker’s primary research focus has involved inflammatory mediators of heart disease and the molecular and genetic epidemiology of hemostasis and thrombosis, with particular interests in biomarkers for coronary disease, “predictive” medicine, and the underlying causes and prevention of atherosclerotic disease.

View full profile